Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Convertible Debt: 2022

Historic Convertible Debt for SAB Biotherapeutics (SABS) over the last 1 years, with Dec 2022 value amounting to $541,644.

  • SAB Biotherapeutics' Convertible Debt was N/A to $541,644 in Q2 2023 from the same period last year, while for Jun 2023 it was $541,644, marking a year-over-year change of. This contributed to the annual value of $541,644 for FY2022, which is N/A change from last year.
  • Latest data reveals that SAB Biotherapeutics reported Convertible Debt of $541,644 as of FY2022.
  • SAB Biotherapeutics' Convertible Debt's 5-year high stood at $541,644 during FY2022, with a 5-year trough of $541,644 in FY2022.
  • Its 1-year average for Convertible Debt is $541,644, with a median of $541,644 in 2022.